Fast track — ArticlesRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Introduction
The American College of Chest Physicians recommends prophylaxis for venous thromboembolism for at least 10 days after total knee arthroplasty (grade 1A recommendation).1 Given the trend for shorter hospital stays,2 a simple, effective, oral anticoagulant regimen for use in an outpatient setting would be beneficial. Rivaroxaban is a new oral agent that directly inhibits factor Xa, an enzyme of the coagulation cascade involved in the formation of thrombin.
RECORD4 (Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism) is a multicentre, randomised, double-blind trial designed to assess the efficacy and safety of oral rivaroxaban 10 mg once daily compared with 30 mg enoxaparin given subcutaneously every 12 h, for the prevention of venous thromboembolism after elective total knee arthroplasty. RECORD4 differs from the previously reported RECORD trials,3, 4, 5 in comparing rivaroxaban with the 30 mg every 12 h enoxaparin regimen approved in North America for the prevention of venous thromboembolism after total knee arthroplasty.
Section snippets
Patients
Patients were eligible for the study if they were aged 18 years or older and were scheduled for total knee arthroplasty. Patients were excluded if they had active bleeding or a high risk of bleeding, or any disorder contraindicating the use of enoxaparin or that might necessitate enoxaparin dose adjustment. Other exclusion criteria included disorders preventing bilateral venography, clinically significant liver disease, severe renal impairment (creatinine clearance <30 mL per min), concomitant
Results
Between June, 2006, and October, 2007, 3418 patients were enrolled in 131 centres in 12 countries (figure), and of these, 3148 patients were randomly assigned treatment. 1742 patients were included in the per-protocol population, and 1924 in the modified intention-to-treat population. The reasons for exclusion from the various populations were similar in the rivaroxaban and enoxaparin groups (table 1). Proportions of patients with venograms adequate for assessment for the primary efficacy
Discussion
Oral, once-daily rivaroxaban 10 mg was more efficacious than subcutaneous enoxaparin 30 mg for the prevention of venous thromboembolism after total knee arthroplasty. Rivaroxaban significantly reduced the absolute risk of total venous thromboembolism by 3·2% (relative risk reduction 31%). Although there were more major, major plus clinically relevant non-major, and any bleeding events with rivaroxaban, the differences compared with enoxaparin were not statistically significant.
Previous phase
References (15)
- et al.
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)
Chest
(2008) - et al.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Lancet
(2008) - et al.
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study
J Thromb Haemost
(2003) - et al.
Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial
Blood (ASH Annual Meeting Abstracts)
(2008) - et al.
Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty
Blood (ASH Annual Meeting Abstracts)
(2008) - et al.
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery
Chest
(2003) - et al.
Compliance with antithrombotic guidelines
Manag Care
(2006)
Cited by (908)
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
2024, Journal of the American College of CardiologySafety and Efficacy of Rivaroxaban in Primary Total Hip and Knee Arthroplasty
2023, Journal of ArthroplastyJoint 2022 European Society of Thoracic Surgeons and The American Association for Thoracic Surgery guidelines for the prevention of cancer-associated venous thromboembolism in thoracic surgery
2023, Journal of Thoracic and Cardiovascular SurgeryRivaroxaban versus enoxaparin for thromboprophylaxis in orthopedic surgery: A meta-analysis
2023, Revista Espanola de Cirugia Ortopedica y Traumatologia
- ‡
Investigators listed at end of paper